What is Lifesci Capital’s Forecast for TECX FY2025 Earnings?

Tectonic Therapeutic, Inc. (NASDAQ:TECX) – Lifesci Capital issued their FY2025 earnings per share estimates for Tectonic Therapeutic in a research report issued to clients and investors on Thursday, February 5th. Lifesci Capital analyst G. Maini anticipates that the company will post earnings of ($4.72) per share for the year. Lifesci Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Tectonic Therapeutic’s current full-year earnings is ($8.31) per share. Lifesci Capital also issued estimates for Tectonic Therapeutic’s Q4 2025 earnings at ($1.21) EPS.

Several other analysts have also commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tectonic Therapeutic in a research report on Thursday, January 22nd. Truist Financial decreased their price target on shares of Tectonic Therapeutic from $64.00 to $60.00 and set a “buy” rating for the company in a research note on Thursday, January 8th. Finally, Wells Fargo & Company started coverage on shares of Tectonic Therapeutic in a report on Monday, October 20th. They issued an “overweight” rating and a $101.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $81.50.

Tectonic Therapeutic Stock Performance

Shares of NASDAQ:TECX opened at $24.37 on Monday. The company has a market capitalization of $456.21 million, a P/E ratio of -6.31 and a beta of 3.71. The company’s 50-day moving average is $20.35 and its 200 day moving average is $19.61. Tectonic Therapeutic has a fifty-two week low of $13.70 and a fifty-two week high of $42.76.

Tectonic Therapeutic (NASDAQ:TECX) last announced its earnings results on Thursday, November 6th. The company reported ($1.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.05) by $0.03.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in TECX. Millennium Management LLC increased its position in shares of Tectonic Therapeutic by 726.4% during the first quarter. Millennium Management LLC now owns 237,938 shares of the company’s stock valued at $4,214,000 after buying an additional 209,145 shares during the period. Goldman Sachs Group Inc. grew its stake in Tectonic Therapeutic by 331.1% during the first quarter. Goldman Sachs Group Inc. now owns 104,793 shares of the company’s stock valued at $1,856,000 after acquiring an additional 80,483 shares in the last quarter. Jane Street Group LLC increased its holdings in Tectonic Therapeutic by 58.7% during the 1st quarter. Jane Street Group LLC now owns 47,145 shares of the company’s stock worth $835,000 after acquiring an additional 17,443 shares during the period. AlphaQuest LLC increased its holdings in Tectonic Therapeutic by 919.4% during the 2nd quarter. AlphaQuest LLC now owns 2,365 shares of the company’s stock worth $47,000 after acquiring an additional 2,133 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its stake in Tectonic Therapeutic by 3.1% in the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 35,708 shares of the company’s stock worth $710,000 after purchasing an additional 1,063 shares in the last quarter. Institutional investors own 62.63% of the company’s stock.

Tectonic Therapeutic Company Profile

Tectonic Therapeutic, Inc engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.